Nano Smart Pharma collaborates with University of California

By Admin
Private biotechnology company NanoSmart Pharmaceuticals has signed a research collaboration agreement with University of California to continue the dev...

Private biotechnology company NanoSmart Pharmaceuticals has signed a research collaboration agreement with University of California to continue the development of NanoSmart’s novel drug delivery platform to treat cancer and other life-threatening diseases.

Dr. James Smith, President of NanoSmart Pharmaceuticals said, “We are very excited to work closely with Dr. Noah Federman and his colleagues at ULCA, as they will provide access to an extraordinary level of research, development and clinical resources.”

Mr. Smith also said, “Their expertise in the development of nanotechnology-based drugs will enable us to continue making efficient progress towards commercializing these products.”

NanoSmart’s patented platform drug delivery system utilizes human autoimmune antibodies that target many different types of tumors. When combined with already FDA-approved drugs, this patented technology allows for the creation of a broad range of next-generation, safer and more effective cancer drug products.

Dr. Noah Federman, Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, a part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center; and Assistant Professor of Pediatrics, Hematology/Oncology at Mattel Children's Hospital at UCLA, said, “Despite the extensive research into new drug formulations, the pace of advancing benefit to this patient population is unfortunately slowing.” He also said, “We are pleased to collaborate with NanoSmart to help drive the development of these much-needed products."

UCLA’s Jonsson Comprehensive Cancer Center is the nation’s largest top-ranked comprehensive cancer research centers.

NanoSmart Pharmaceuticals, Inc is developing novel proprietary drug delivery products to treat cancer and other serious life threatening diseases.  It has completed development of its preliminary immunoliposomal formulations and is currently engaged in preclinical testing of it lead candidate drug products. 

Share
Share

Featured Articles

Digital healthcare platform Balanced supports healthy ageing

10,000 people turn 65 in the USA each day. Digital healthcare platform Balanced wants to help them better manage healthy ageing, says CEO Katie Reed

TrueBinding’s antibody drugs fight Alzheimer’s Disease

Dongxu Sun, CEO at TrueBinding, shares how its research & antibody drug development is fighting illnesses such as Alzheimer’s Disease, stroke & more

Cardinal Health’s clinically integrated pharma supply chain

Peter J. Siavelis, SVP & General Manager, Health System & Provider Distribution & Services at Cardinal Health, discusses the integrated pharma supply chain

Healthcare Digital news roundup: digital healthcare & AI

Digital Healthcare

Hospitals must embrace IoMT device security

Hospitals

Mental health support for working women and mothers

Digital Healthcare